Literature DB >> 1513094

Eight to nine year mortality in known non-insulin dependent diabetics and controls.

E M Damsgaard1, A Frøland, O D Jørgensen, C E Mogensen.   

Abstract

Microalbuminuria is known to predict mortality in elderly, non-insulin dependent diabetic individuals. To test whether this is also so when studied prospectively and over a longer period, we followed 228 persons with known diabetes mellitus and an age and sex matched, non-diabetic cohort for eight to nine years. Both cohorts were found during a population screening in 1981-1982 of 5292 citizens aged 60 to 74 years. At ascertainment extensive clinical and biochemical examinations including determination of urinary albumin were carried out. At May 15, 1990 111 diabetic and 46 non-diabetics had died (P less than 0.0001). In the diabetic cohort the median value of urinary albumin excretion (UAE) was 17.40 micrograms/min. In the group with values at or above 17.40 micrograms/min 62 died, compared with 40 deaths in the group with values below (P = 0.003). In the non-diabetic cohort the median UAE value was 7.52 micrograms/min. In the upper group 26 died, in the lower 15 (P = 0.05). Cox regression analyses showed coefficients of regression for ln(UAE) of 0.333 (P less than 0.001) for the diabetic group and 0.236 (P = 0.048) for the non-diabetic group. In the Cox model for the diabetics, ischemic heart disease was also of independent significance to mortality. The final model for the non-diabetics included hypertension and sex as significant variables. It is concluded that in a prospective study of elderly diabetics urinary albumin excretion rate is the best prognostic factor for long-term mortality.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1513094     DOI: 10.1038/ki.1992.114

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  Preventive medicine in people at high risk for chronic disease: the value of identifying and treating diabetes.

Authors:  H C Gerstein; S Meltzer
Journal:  CMAJ       Date:  1999-06-01       Impact factor: 8.262

Review 2.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

3.  Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM.

Authors:  Y Doi; H Yoshizumi; M Yoshinari; K Iino; M Yamamoto; K Ichikawa; M Iwase; M Fujishima
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

Review 4.  Renal function changes in middle-aged and elderly Caucasian type 2 (non-insulin-dependent) diabetic patients--a review.

Authors:  A Schmitz
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

Review 5.  Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes.

Authors:  K G Dawson; J K McKenzie; S A Ross; J L Chiasson; P Hamet
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

6.  Danish general practitioners' estimation of urinary albumin concentration in the detection of proteinuria and microalbuminuria.

Authors:  N D Olivarius; C E Mogensen
Journal:  Br J Gen Pract       Date:  1995-02       Impact factor: 5.386

7.  Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.

Authors:  C Rangemark; H Lind; L Lindholm; T Hedner; O Samuelsson
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 8.  Cost-effective strategies in the prevention of diabetic nephropathy.

Authors:  Jonathan D Rippin; Anthony H Barnett; Stephen C Bain
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM.

Authors:  A Schmitz; M Vaeth; C E Mogensen
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

10.  Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Authors:  Jorge Calles-Escandón; Laura C Lovato; Denise G Simons-Morton; David M Kendall; Rodica Pop-Busui; Robert M Cohen; Denise E Bonds; Vivian A Fonseca; Faramarz Ismail-Beigi; Mary Ann Banerji; Alan Failor; Bruce Hamilton
Journal:  Diabetes Care       Date:  2010-01-26       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.